<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570192</url>
  </required_header>
  <id_info>
    <org_study_id>10-0060</org_study_id>
    <nct_id>NCT01570192</nct_id>
  </id_info>
  <brief_title>Clinical Trials to Reduce the Risk of Antimicrobial Resistance</brief_title>
  <official_title>Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate a low rate of emergence of antibiotic
      resistance in P. aeruginosa and Acinetobacter spp during the treatment of hospitalized
      patients with pneumonia requiring mechanical ventilation treated with PD optimized meropenem
      administered as a prolonged infusion in combination with a parenteral aminoglycoside plus
      tobramycin by inhalation (Group 1) compared to therapy with meropenem alone (Group 2 -
      control arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this clinical study is to demonstrate that the application of pharmacodynamic
      dosing principles to the antibiotic treatment of hospitalized subjects with
      culture-documented pneumonia (including HABP, VABP and HCAP) requiring mechanical ventilation
      can inhibit the emergence of antibiotic-resistant organisms during treatment and therefore
      may improve the rate of a satisfactory clinical response. Antibiotic resistance is defined as
      an increase in meropenem or aminoglycoside MIC by two tube dilutions (fourfold) from
      baseline. In animal models of infection, the pharmacodynamic driver for bactericidal effect
      by Î² lactam antibiotics such as meropenem is the proportion of the dosing interval during
      which plasma drug levels are maintained above the MIC of the causative pathogen. The
      hypothesis of this study is that prolongation of time above MIC by increasing total meropenem
      dose and the duration of infusion will counter-select for the emergence of antimicrobial
      resistance during the treatment of hospitalized subjects with pneumonia (i.e. HABP, VABP and
      HCAP) caused by P.aeruginosa, Acinetobacter species (spp), or other pathogens with
      intermediate susceptibility to meropenem, and that the addition of parenteral aminoglycosides
      (amikacin, tobramycin or gentamicin) and nebulized aminoglycoside (tobramycin) given along
      optimal pharmacodynamic principles will further reduce the likelihood of resistance
      emergence, particularly among the non-fermenting Gram-negative bacilli, such as Pseudomonas
      aeruginosa and Acinetobacter spp. The observed incidence of resistance emergence to meropenem
      will be compared across therapeutic regimens.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    NIAID terminated the study due to low subject enrollment
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is an open-label study with 1:1 randomization between two active treatment groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Suppression and Emergence of Resistance</measure>
    <time_frame>up to 28 days after enrollment</time_frame>
    <description>The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
    <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response in Subjects Who Received Prior Antibiotics</measure>
    <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
    <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Microbiologic Response</measure>
    <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
    <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pretreatment Pathogen Response</measure>
    <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
    <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suppression of the Emergence of Resistance in Other Gram-negative Pathogens</measure>
    <time_frame>Day 5/Early Extubation</time_frame>
    <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Repeat Negative Cultures</measure>
    <time_frame>Day 5/Early Extubation</time_frame>
    <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>14 days</time_frame>
    <description>Percentage of patients who died by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of patients who died by efficacy endpoint, treatment group and population (n/N)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>IV meropenem; parenteral aminoglycoside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to this group will receive:
IV meropenem (2 g infused over 3 hrs q 8 hr);
a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
tobramycin nebulization
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I.V. Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.
**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV meropenem</intervention_name>
    <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).</description>
    <arm_group_label>IV meropenem; parenteral aminoglycoside</arm_group_label>
    <other_name>Merrem I.V.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I.V. Meropenem</intervention_name>
    <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage</description>
    <arm_group_label>I.V. Meropenem</arm_group_label>
    <other_name>Merrem I.V.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h</intervention_name>
    <description>a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)</description>
    <arm_group_label>IV meropenem; parenteral aminoglycoside</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.</intervention_name>
    <description>Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.</description>
    <arm_group_label>IV meropenem; parenteral aminoglycoside</arm_group_label>
    <arm_group_label>I.V. Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tobramycin nebulization</intervention_name>
    <description>tobramycin nebulization 600mg/day</description>
    <arm_group_label>IV meropenem; parenteral aminoglycoside</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Written informed consent by the subject/subject's LAR.

        Hospitalized males or females â¥ 18 yrs with respiratory failure requiring mechanical
        ventilation and clinical suspicion of HABP, HCAP or VABP.

        Onset or exacerbation of pneumonia at least 48 hours after admission to any patient health
        care facility or onset of pneumonia in a nursing home or rehabilitation facility with
        subsequent transfer to an acute care facility

        Women of childbearing potential if their pregnancy test is negative

        Subjects who have received previous antibacterial therapy within 14 days of pre-treatment
        bronchoscopy entry may be entered only if the subject has not responded clinically.). While
        less than 24 hours of pre-treatment antibiotics is preferential, recovery of &gt;104 CFU/ml in
        the quantitative Bronchoscopic BAL will be seen as primary evidence that the prior therapy
        was not efficacious and enrollment will be allowed.)

        Patients should have clinical findings that support a diagnosis of HABP/VABP/HCAP:

        Within 48 hours before starting empiric therapy a subject's chest radiograph should show
        the presence of a NEW or progressive infiltrate, cavitation, or effusion suggestive of
        pneumonia

        Within 36 hours before the start of empiric study therapy, a quantitative culture of
        Bronchoscopic BAL fluid must be obtained.

        Patients with VABP should have a Clinical Pulmonary Infection Score of &gt;/= 5.

        Exclusion Criteria:

        Subjects with pneumonia caused by pathogens resistant to meropenem (MIC greater than or
        equal to 16Âµg/ml) or a prior meropenem therapy failure.

        Subjects with contra-indications to ANY study medication, in particular with known or
        suspected allergy or hypersensitivity.

        Women who are pregnant or lactating.

        Subjects taking anticonvulsant medications for a known seizure disorder.Patients with a
        history of seizures, AND who are stabilized on anti-seizure medication, may be enrolled
        into the study at the discretion of the site investigator.

        Subjects with known or suspected community acquired bacterial pneumonia (CABP) or viral
        pneumonia; or Subjects with acute exacerbation of chronic bronchitis without evidence of
        pneumonia.

        Subjects with primary lung cancer or another malignancy metastatic to the lungs.

        Subjects who were previously enrolled in this study.

        Subjects who have had an investigational drug or have used an investigational device within
        30 days prior to entering the study.

        Subjects with another focus of infection requiring concurrent antibiotics that would
        interfere with evaluation of the response to study drug.

        Subjects with cystic fibrosis, AIDS with a CD4 lymphocyte count &lt;200 cells/Âµl, neutropenia
        (absolute neutrophil count &lt;500 cells/ml), known or suspected active tuberculosis.

        Subjects with little chance of survival for the duration of study therapy.

        Subjects with an APACHE II score &gt;35.

        Subjects with underlying condition(s) which would make it difficult to interpret response
        to the study drugs.

        Subjects with hypotension or acidosis despite attempts at fluid resuscitation. Subjects
        requiring ongoing treatment with vasopressors will be eligible for the study if their
        hypotension is controlled and acidosis has resolved. Subjects with intractable septic shock
        are not eligible for enrollment.

        Subjects who have undergone bone marrow transplantation.

        Subjects with profound hypoxia as defined by a PaO2/FiO2 ratio &lt;100.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George L Drusano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InClin, Inc.</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UFL Department of Medicine: Pulmonary, Critical Care and Sleep Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-4250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JMI Laboratories</name>
      <address>
        <city>North Liberty</city>
        <state>Iowa</state>
        <zip>52317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lerner College of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>Cedex 13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Clinical Trial Center GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med. 1996 May;153(5):1711-25. Review.</citation>
    <PMID>8630626</PMID>
  </reference>
  <reference>
    <citation>Bauernfeind A, Jungwirth R. In Vitro Activity of SM 7338 and Imipenem. 28th ICAAC, Los Angeles, October 1988. Abstract 599</citation>
  </reference>
  <reference>
    <citation>Calandra GB, Hesney M, Brown KR. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial. Clin Ther. 1985;7(2):225-38.</citation>
    <PMID>3886144</PMID>
  </reference>
  <reference>
    <citation>Clarke AM, Zemcov SJV. SM 7338 (ICI 194,660), A New DHP-1 Stable Carbapenem; In Vitro Activity Against a Wide Range of Canadian Clinical Isolates. 28th ICAAC, Los Angeles, October 1988. Abstract 598.</citation>
  </reference>
  <reference>
    <citation>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. Review.</citation>
    <PMID>9455502</PMID>
  </reference>
  <reference>
    <citation>Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997 Feb;24 Suppl 2:S266-75. Review.</citation>
    <PMID>9126702</PMID>
  </reference>
  <reference>
    <citation>Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 2003 Aug;23(8):988-91.</citation>
    <PMID>12921245</PMID>
  </reference>
  <reference>
    <citation>Data on file. Drug Development Department, AstraZeneca Pharmaceuticals, Wilmington,DE 19897.</citation>
  </reference>
  <reference>
    <citation>Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003 Jan 15;36(Suppl 1):S42-50.</citation>
    <PMID>12516029</PMID>
  </reference>
  <reference>
    <citation>Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother. 2009 Jun;53(6):2266-73. doi: 10.1128/AAC.01680-08. Epub 2009 Mar 16.</citation>
    <PMID>19289521</PMID>
  </reference>
  <reference>
    <citation>Edwards JR, Wannop C. SM 7338, A New Carbapenem Antibacterial: In Vitro Activity Against Imipenem-Resistant Ps. aeruginosa. 27th ICAAC, New York October 1987, Abstract 754.</citation>
  </reference>
  <reference>
    <citation>Edwards JR, Turner PJ, Withnell ES, et al. SM 7338, A New Carbapenem Antibacterial: In Vitro Activity Against Bacterial Strains of Clinical Origins. 27th ICAAC, New York, October 1987, Abstract 755.</citation>
  </reference>
  <reference>
    <citation>Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindey AJ, Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1989 Feb;33(2):215-22.</citation>
    <PMID>2655530</PMID>
  </reference>
  <reference>
    <citation>Fagon JY, Chastre J, Novara A, Medioni P, Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med. 1993;19(3):137-44.</citation>
    <PMID>8315120</PMID>
  </reference>
  <reference>
    <citation>Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994 Mar;38(3):547-57.</citation>
    <PMID>8203853</PMID>
  </reference>
  <reference>
    <citation>Fukasawa M, Sumita Y, Tada E, et al. SM 7338, A New Carbapenem Antibacterial: In Vitro Activity Against 1607 Clinical Strains of Gram-Positive and Gram-Negative Pathogens. 27th ICAAC, New York, October 1987, Abstract 753.</citation>
  </reference>
  <reference>
    <citation>Fukasawa M, Tada E, Nouda H, et al. Induction and Inhibition of b-Lactamases by SM 7338; A Novel Carbapenem Antibacterial. 28th ICAAC, Los Angeles, October 1988. Abstract 606.</citation>
  </reference>
  <reference>
    <citation>Hamacher J, Vogel F, Lichey J, Kohl FV, Diwok K, Wendel H, Lode H. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group. J Antimicrob Chemother. 1995 Jul;36 Suppl A:121-33.</citation>
    <PMID>8543488</PMID>
  </reference>
  <reference>
    <citation>Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1249-56.</citation>
    <PMID>10194173</PMID>
  </reference>
  <reference>
    <citation>Investigational Brochure, Drug Development Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19897.</citation>
  </reference>
  <reference>
    <citation>Jones RN, Barry AL, et al. Antimicrobial Activity of SM 7338, A New DHP-1 Stable Carbapenem. 28th ICAAC, Los Angeles, October 1988. Abstract 597.</citation>
  </reference>
  <reference>
    <citation>Kayser FH, Morenzoni G. Activity of SM 7338, A New Carbapenem Antibacterial Against Gram-Positive Bacteria. 28th ICAAC, Los Angeles, October 1988. Abstract 603.</citation>
  </reference>
  <reference>
    <citation>Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999 Feb;115(2):462-74.</citation>
    <PMID>10027448</PMID>
  </reference>
  <reference>
    <citation>Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995 Dec;108(6):1655-62.</citation>
    <PMID>7497777</PMID>
  </reference>
  <reference>
    <citation>Lancero MG, Young LS. In Vitro Studies with SM 7338; A Novel Carbapenem with Broad Bactericidal Activity. 28th ICAAC, Los Angeles, October 1988. Abstract 602.</citation>
  </reference>
  <reference>
    <citation>Lode H, Hamacher J, Eller J, Schaberg T. Changing role of carbapenems in the treatment of lower respiratory tract infections. Scand J Infect Dis Suppl. 1995;96:17-23. Review.</citation>
    <PMID>7652498</PMID>
  </reference>
  <reference>
    <citation>Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997 Mar;111(3):676-85.</citation>
    <PMID>9118708</PMID>
  </reference>
  <reference>
    <citation>McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am. 1998 Sep;12(3):761-79, x. Review.</citation>
    <PMID>9779389</PMID>
  </reference>
  <reference>
    <citation>Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest. 1992 Nov;102(5 Suppl 1):557S-564S. Review.</citation>
    <PMID>1424930</PMID>
  </reference>
  <reference>
    <citation>Moellering RC Jr, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother. 1989 Sep;24 Suppl A:1-7. Review.</citation>
    <PMID>2681123</PMID>
  </reference>
  <reference>
    <citation>Neu HG, Saha G, Chin NX. In Vitro Activity of SM 7338; A New Carbapenem, Compared with Other Antibacterials Against Multiply Resistant Bacteria. 28th ICAAC, Los Angeles, October 1988. Abstract 601.</citation>
  </reference>
  <reference>
    <citation>Nord CE, Lindmark A, Persson I. Susceptibility of Anaerobic Bacteria to SM 7338. 28th ICAAC, Los Angeles, October 1988. Abstract 596.</citation>
  </reference>
  <reference>
    <citation>Okuda T, Fukasawa M, Tanio T, et al. SM 7338, A New Carbapenem Antibacterial: In Vitro and In Vivo Antibacterial Activities. 27th ICAAC, New York, October 1987. Abstract 757.</citation>
  </reference>
  <reference>
    <citation>Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis. 1988 Jul-Aug;10(4):892-8. Review.</citation>
    <PMID>3142013</PMID>
  </reference>
  <reference>
    <citation>Sanford Guide to Antimicrobial Therapy. Thirty-third Edition, 2003. Gilbert DN, Moellering RC, Sande MA.</citation>
  </reference>
  <reference>
    <citation>Scheld WM, Mandell GL. Nosocomial pneumonia: pathogenesis and recent advances in diagnosis and therapy. Rev Infect Dis. 1991 Jul-Aug;13 Suppl 9:S743-51. Review.</citation>
    <PMID>1925319</PMID>
  </reference>
  <reference>
    <citation>Slaney L, Chubb H, Mohammed Z, et al. In Vitro Activity of SM 7338 Against Neisseria gonorrhoeae (Gc), Haemophilus ducreyi (Hd) and Haemophilus influenzae. 28th ICAAC, Los Angeles, October 1988. Abstract 604.</citation>
  </reference>
  <reference>
    <citation>Strasbaugh LJ. Nosocomial repiratory infections. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. Philadelphia: Churchill Livingstone, 2000: 3021-3026.</citation>
  </reference>
  <reference>
    <citation>Sumita Y, Fukasawa M, Okunda T. SM 7338, A New Carbapenem Antibacterial: Affinities for PBP's and Morphological Changes. 27th ICAAC, New York, October 1987. Abstract 756.</citation>
  </reference>
  <reference>
    <citation>Sumita Y, Inoue M, Mitsuhashi S. In Vitro Antibacterial Activity of SM 7338. 28th ICAAC, Los Angeles, October 1988. Abstract 600.</citation>
  </reference>
  <reference>
    <citation>Sunagawa M, Matsumura H, Inoue T, et al. SM 7338, A New Carbapenem Antibacterial: Structure-Activity Relations and Physiochemical Properties. 27th ICAAC, New York, October 1987. Abstract 752.</citation>
  </reference>
  <reference>
    <citation>TALKE H, SCHUBERT GE. [ENZYMATIC UREA DETERMINATION IN THE BLOOD AND SERUM IN THE WARBURG OPTICAL TEST]. Klin Wochenschr. 1965 Feb 1;43:174-5. German.</citation>
    <PMID>14258517</PMID>
  </reference>
  <reference>
    <citation>Torres A, Aznar R, Gatell JM, JimÃ©nez P, GonzÃ¡lez J, Ferrer A, Celis R, Rodriguez-Roisin R. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis. 1990 Sep;142(3):523-8.</citation>
    <PMID>2202245</PMID>
  </reference>
  <reference>
    <citation>Torres A, Bauer TT, LeÃ³n-Gil C, Castillo F, Alvarez-Lerma F, MartÃ­nez-PellÃºs A, Leal-Noval SR, Nadal P, Palomar M, Blanquer J, Ros F. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax. 2000 Dec;55(12):1033-9.</citation>
    <PMID>11083889</PMID>
  </reference>
  <reference>
    <citation>Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998 Feb;157(2):531-9.</citation>
    <PMID>9476869</PMID>
  </reference>
  <reference>
    <citation>Vetter N. The Use of Meropenem ('Merrem'/'Meronen') in the Therapy of Hospital-acquired Lower Respiratory Infections: a Review of Clinical Experience. 18th International Congress of Chemotherapy, Stockholm, Sweden, 27 June-2 July, 1993. Abstract 70.</citation>
  </reference>
  <reference>
    <citation>Wise R, Andrews JM, Ashby JP. The Bactericidal Activity of the Carbapenem, SM 7338, Alone and in Combination. 28th ICAAC, Los Angeles, October 1988. Abstract 605.</citation>
  </reference>
  <reference>
    <citation>World Health Organization. Draft Global Strategy for the Containment of Antimicrobial Resistance. Available on the Internet at http://www.who.int/emc/amr.htm</citation>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <results_first_submitted>December 22, 2016</results_first_submitted>
  <results_first_submitted_qc>March 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2017</results_first_posted>
  <disposition_first_submitted>March 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2016</disposition_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gram negative pathogens</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Acinetobacter</keyword>
  <keyword>HCAP</keyword>
  <keyword>VABP</keyword>
  <keyword>HABP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We had 8 clinical sites: recruitment into the study began September 2010 and ended April 10, 2015.</recruitment_details>
      <pre_assignment_details>Enrolled participants were excluded from the trial before assignment to groups because participants had no qualifying organisms; this includes participants with no growth on screening BAL, those with &lt; 104 CFU/mL on BAL, and those with only Gram-positive bacteria cultured from the BAL.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Meropenem; Parenteral Aminoglycoside</title>
          <description>Subjects assigned to this group will receive:
IV meropenem (2 g infused over 3 hrs q 8 hr);
a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
tobramycin nebulization
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens.
IV meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
tobramycin nebulization: tobramycin nebulization 600mg/day</description>
        </group>
        <group group_id="P2">
          <title>I.V. Meropenem</title>
          <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.
**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion.
I.V. Meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>no qualifying organism</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>changed to palliative care</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of patients enrolled in the study and who had a baseline BAL.</population>
      <group_list>
        <group group_id="B1">
          <title>IV Meropenem; Parenteral Aminoglycoside</title>
          <description>Subjects assigned to this group will receive:
IV meropenem (2 g infused over 3 hrs q 8 hr);
a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
tobramycin nebulization
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens.
IV meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
tobramycin nebulization: tobramycin nebulization 600mg/day</description>
        </group>
        <group group_id="B2">
          <title>I.V. Meropenem</title>
          <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.
**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion.
I.V. Meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="18.3"/>
                    <measurement group_id="B2" value="58.4" spread="12.6"/>
                    <measurement group_id="B3" value="59.2" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline acute physiology and chronic health evaluation II (APACHE II) score</title>
          <description>A severity of disease classification system applied within 24 hours of patient admission to an ICU. The point score is calculated from a patient's age and physiological measurements. The range of score is between 0-71. Physiological measurements and all ages fit into that range. Note: the higher the score, the higher the probability of death.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.6" spread="4.6"/>
                    <measurement group_id="B2" value="21.0" spread="6.2"/>
                    <measurement group_id="B3" value="21.5" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Suppression and Emergence of Resistance</title>
        <description>The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE.</description>
        <time_frame>up to 28 days after enrollment</time_frame>
        <population>All patients in the ME population with BAL at baseline and at Day 5/EE and pathogens collected at baseline BAL and at Day 5/EE BAL.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Meropenem; Parenteral Aminoglycoside</title>
            <description>Subjects assigned to this group will receive:
IV meropenem (2 g infused over 3 hrs q 8 hr);
a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
tobramycin nebulization
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens.
IV meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
tobramycin nebulization: tobramycin nebulization 600mg/day</description>
          </group>
          <group group_id="O2">
            <title>I.V. Meropenem</title>
            <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.
**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion.
I.V. Meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suppression and Emergence of Resistance</title>
          <description>The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE.</description>
          <population>All patients in the ME population with BAL at baseline and at Day 5/EE and pathogens collected at baseline BAL and at Day 5/EE BAL.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>suppression of emergence of resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>emergence of resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response</title>
        <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>MEGroup - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response</title>
          <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response in Subjects Who Received Prior Antibiotics</title>
        <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response in Subjects Who Received Prior Antibiotics</title>
          <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Microbiologic Response</title>
        <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Microbiologic Response</title>
          <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pretreatment Pathogen Response</title>
        <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>End of treatment - up to 28 days after enrollment</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Pretreatment Pathogen Response</title>
          <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Suppression of the Emergence of Resistance in Other Gram-negative Pathogens</title>
        <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>Day 5/Early Extubation</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Suppression of the Emergence of Resistance in Other Gram-negative Pathogens</title>
          <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Repeat Negative Cultures</title>
        <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>Day 5/Early Extubation</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Repeat Negative Cultures</title>
          <description>Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Percentage of patients who died by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>14 days</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Percentage of patients who died by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Percentage of patients who died by efficacy endpoint, treatment group and population (n/N)</description>
        <time_frame>28 days</time_frame>
        <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ME Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population</description>
          </group>
          <group group_id="O2">
            <title>ME Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologic Evaluable (ME) group and population.</description>
          </group>
          <group group_id="O3">
            <title>m-MITT Group - Meropenem Plus Aminoglycoside</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
          <group group_id="O4">
            <title>m-MITT Group - Meropenem Only</title>
            <description>Percentage of patients with successful responses by efficacy endpoint, Microbiologically modified ITT (m-MITT) group and population.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Percentage of patients who died by efficacy endpoint, treatment group and population (n/N)</description>
          <population>The ME population, 19 subjects were analyzed and the m-MITT population, 24 were analyzed. Not all subjects were evaluable for each endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IV Meropenem; Parenteral Aminoglycoside</title>
          <description>Subjects assigned to this group will receive:
IV meropenem (2 g infused over 3 hrs q 8 hr);
a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
tobramycin nebulization
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens.
IV meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h: a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
tobramycin nebulization: tobramycin nebulization 600mg/day</description>
        </group>
        <group group_id="E2">
          <title>I.V. Meropenem</title>
          <description>Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.
**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion.
I.V. Meropenem: Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage
Linezolid or Vancomcin (per institutional guidelines) will be available for MRSA coverage.: Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>AICD fired/NSTEMI</sub_title>
                <description>Note: this patient in group 2 (IV mero only) experienced 2 SAES that occurred in separate organ systems: AICD fired/NSTEMI and COPD with acute exacerbation. Therefore, this patient was counted twice.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PEA arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>reinforced duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>multi-organ failure due to distributive and cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <description>Note: this patient in group 2 (IV mero only) experienced 2 SAES that occurred in separate organ systems: Pulmonary embolism and stroke.. Therefore, this patient was counted twice.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <description>Note: this patient in group 2 (IV mero only) experienced 2 SAES that occurred in separate organ systems: Pulmonary embolism and stroke. Therefore, this patient was counted twice.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>refractory shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>cardiorespiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneomonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>COPD with acute exacerbation</sub_title>
                <description>Note: this patient in group 2 (IV mero only) experienced 2 SAES that occurred in separate organ systems: AICD fired/NSTEMI and COPD with acute exacerbation. Therefore, this patient was counted twice.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cutaneous eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. George L. Drusano</name_or_title>
      <organization>University of Florida, Department of Medicine</organization>
      <phone>407-313-7060</phone>
      <email>gdrusano@ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

